Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · IEX Real-Time Price · USD
27.59
+1.10 (4.15%)
At close: May 2, 2024, 4:00 PM
28.29
+0.70 (2.54%)
After-hours: May 2, 2024, 5:23 PM EDT
Anika Therapeutics Revenue
In the year 2023, Anika Therapeutics had annual revenue of $166.66M with 6.67% growth. Revenue in the quarter ending December 31, 2023 was $42.97M with 8.45% year-over-year growth.
Revenue (ttm)
$166.66M
Revenue Growth
+6.67%
P/S Ratio
2.45
Revenue / Employee
$466,840
Employees
357
Market Cap
409.12M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166.66M | 10.43M | 6.67% |
Dec 31, 2022 | 156.24M | 8.44M | 5.71% |
Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
Dec 31, 2018 | 105.56M | -7.87M | -6.93% |
Dec 31, 2017 | 113.42M | 10.04M | 9.71% |
Dec 31, 2016 | 103.38M | 10.38M | 11.16% |
Dec 31, 2015 | 93.00M | -12.60M | -11.93% |
Dec 31, 2014 | 105.60M | 30.51M | 40.64% |
Dec 31, 2013 | 75.08M | 3.72M | 5.22% |
Dec 31, 2012 | 71.36M | 6.58M | 10.16% |
Dec 31, 2011 | 64.78M | 9.22M | 16.60% |
Dec 31, 2010 | 55.56M | 15.42M | 38.42% |
Dec 31, 2009 | 40.14M | 4.36M | 12.17% |
Dec 31, 2008 | 35.78M | 4.95M | 16.06% |
Dec 31, 2007 | 30.83M | 3.99M | 14.86% |
Dec 31, 2006 | 26.84M | -2.99M | -10.04% |
Dec 31, 2005 | 29.83M | 3.37M | 12.73% |
Dec 31, 2004 | 26.47M | 11.06M | 71.81% |
Dec 31, 2003 | 15.40M | 2.22M | 16.81% |
Dec 31, 2002 | 13.19M | 1.88M | 16.58% |
Dec 31, 2001 | 11.31M | -5.02M | -30.75% |
Dec 31, 2000 | 16.34M | 2.51M | 18.15% |
Dec 31, 1999 | 13.83M | 895.28K | 6.92% |
Dec 31, 1998 | 12.93M | 975.03K | 8.16% |
Dec 31, 1997 | 11.96M | 10.74M | 886.38% |
Dec 31, 1996 | 1.21M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nevro | 425.17M |
OraSure Technologies | 405.47M |
Revance Therapeutics | 234.04M |
ADC Therapeutics | 69.56M |
Contineum Therapeutics | 50.00M |
MaxCyte | 41.29M |
Cartesian Therapeutics | 26.00M |
ANIK News
- 14 days ago - Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024 - GlobeNewsWire
- 4 weeks ago - Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Anika Reports Fourth Quarter and Year-End 2023 Financial Results - GlobeNewsWire
- 7 weeks ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024 - GlobeNewsWire
- 2 months ago - Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting - GlobeNewsWire
- 5 months ago - Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release - GlobeNewsWire
- 6 months ago - Anika to Participate in Upcoming Investor Conferences - GlobeNewsWire